Analysis of cytosolic mtDNA release during Staphylococcus aureus infection

Caterina Licini1, Gloria D'Achille2, Nada Dhaouadi1

  • 1Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy.

PubMed

Insights

Methicillin-resistant Staphylococcus aureus (MRSA) infection releases mitochondrial DNA (mtDNA) into the cytoplasm of skin cells. This study details a method to detect and measure this critical mtDNA release following MRSA infection.

Area of Science:

  • Cell Biology
  • Microbiology
  • Immunology

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) is a major pathogen causing severe skin wound infections.
  • MRSA infection initiates a cellular response via mitochondrial pathways, leading to mitochondrial DNA (mtDNA) release into the cytoplasm.
  • Cytosolic mtDNA (cmtDNA) is recognized as foreign, triggering inflammatory responses like inflammasome activation.

Purpose of the Study:

  • To detail a method for detecting and quantifying mtDNA release into the cytoplasm.
  • To investigate mtDNA release in immortalized keratinocytes (HaCaT cells) after MRSA infection.
  • To analyze mtDNA release kinetics at various time points post-infection.

Main Methods:

  • Utilized immortalized keratinocytes (HaCaT cells).
  • Infected cells with Methicillin-resistant Staphylococcus aureus (MRSA).
  • Developed and applied a method to detect and measure cytosolic mtDNA release over time.

Main Results:

  • Successfully detected and measured the release of mtDNA into the cytoplasm of HaCaT cells post-MRSA infection.
  • Quantified mtDNA release at different time intervals following infection.
  • Established a quantifiable assay for studying MRSA-induced mtDNA release.

Conclusions:

  • The study provides a reliable method to assess mtDNA release during MRSA infection in keratinocytes.
  • Understanding mtDNA release is crucial for elucidating inflammatory responses to bacterial pathogens.
  • This method can be applied to study host-pathogen interactions and develop targeted therapies.